Trial reportThe New England journal of medicine2009
Effect of dipyridamole plus aspirin on hemodialysis graft patency.
Trial report in The New England journal of medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 83 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Dipyridamole Plus Aspirin on Hemodialysis Graft Patency
Effect of Beraprost Sodium (Berasil) on Hemodialysis
Who cites it
83 citing papers in PubMed, 6 syntheses or guidelines pooled it, 289 citations in OpenAlex.
- Antiplatelet agents for chronic kidney disease.The Cochrane database of systematic reviews · 2022Pooled it
- Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.The Cochrane database of systematic reviews · 2021Pooled it
- Patency of ePTFE Arteriovenous Graft Placements in Hemodialysis Patients: Systematic Literature Review and Meta-Analysis.Kidney360 · 2020Pooled it
- Effect of antiplatelet therapy on cardiovascular and kidney outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.BMC nephrology · 2019Pooled it
- Medication adherence in randomized controlled trials evaluating cardiovascular or mortality outcomes in dialysis patients: A systematic review.BMC nephrology · 2017Pooled it
- Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts.The Cochrane database of systematic reviews · 2015Pooled it
- The TiME Trial: A Fully Embedded, Cluster-Randomized, Pragmatic Trial of Hemodialysis Session Duration.Journal of the American Society of Nephrology : JASN · 2019Trial
- Bioengineered human acellular vessels for dialysis access in patients with end-stage renal disease: two phase 2 single-arm trials.Lancet (London, England) · 2016Trial
- Trial
- Association of factor V gene polymorphism with arteriovenous graft failure.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2012Trial
- Use of aspirin associates with longer primary patency of hemodialysis grafts.Journal of the American Society of Nephrology : JASN · 2011Trial
- Application of human type I pancreatic elastase (PRT-201) to the venous anastomosis of arteriovenous grafts in patients with chronic kidney disease.The journal of vascular accessTrial
- Effect of local papaverine on arteriovenous fistula maturation in patients with end-stage renal disease.Jornal brasileiro de nefrologiaTrial
- Anticoagulant Use and Frequency of Vascular Access Thrombosis: A Retrospective Cohort Study.The Permanente journal · 2026Article
- Commemorating the National Institute of Diabetes and Digestive and Kidney Diseases' Advances in Kidney Health: 75 Years of Discovery and Impact.Journal of the American Society of Nephrology : JASN · 2026Article
- Clinical and histopathological predictors of secondary arteriovenous fistula failure due to intimal hyperplasia.Frontiers in physiology · 2026Article
- Review
- Commemorating the National Institute of Diabetes and Digestive and Kidney Diseases' Advances in Kidney Health: 75 Years of Discovery and Impact.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Oral Anticoagulant Management for Peripheral Vascular Disease.Advances in surgery · 2025Review
- Structural categorization and identification of electrostatic interactions in two proposed human serum albumin dimerization patterns and dipyridamole interaction.Turkish journal of chemistry · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
27 authors at 18 institutions in 2 countries.
Funding
Abstract
backgroundArteriovenous graft stenosis leading to thrombosis is a major cause of complications in patients undergoing hemodialysis. Procedural interventions may restore patency but are costly. Although there is no proven pharmacologic therapy, dipyridamole may be promising because of its known vascular antiproliferative activity.
methodsWe conducted a randomized, double-blind, placebo-controlled trial of extended-release dipyridamole, at a dose of 200 mg, and aspirin, at a dose of 25 mg, given twice daily after the placement of a new arteriovenous graft until the primary outcome, loss of primary unassisted patency (i.e., patency without thrombosis or requirement for intervention), was reached. Secondary outcomes were cumulative graft failure and death. Primary and secondary outcomes were analyzed with the use of a Cox proportional-hazards regression with adjustment for prespecified covariates.
resultsAt 13 centers in the United States, 649 patients were randomly assigned to receive dipyridamole plus aspirin (321 patients) or placebo (328 patients) over a period of 4.5 years, with 6 additional months of follow-up. The incidence of primary unassisted patency at 1 year was 23% (95% confidence interval [CI], 18 to 28) in the placebo group and 28% (95% CI, 23 to 34) in the dipyridamole-aspirin group, an absolute difference of 5 percentage points. Treatment with dipyridamole plus aspirin significantly prolonged the duration of primary unassisted patency (hazard ratio, 0.82; 95% CI, 0.68 to 0.98; P=0.03) and inhibited stenosis. The incidences of cumulative graft failure, death, the composite of graft failure or death, and serious adverse events (including bleeding) did not differ significantly between study groups.
conclusionsTreatment with dipyridamole plus aspirin had a significant but modest effect in reducing the risk of stenosis and improving the duration of primary unassisted patency of newly created grafts. (ClinicalTrials.gov number, NCT00067119.)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.